BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33579185)

  • 1. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
    Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
    Shi XN; Li H; Yao H; Liu X; Li L; Leung KS; Kung HF; Lu D; Wong MH; Lin MC
    PLoS One; 2015; 10(7):e0132072. PubMed ID: 26147897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
    Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
    Dai XY; Zeng XX; Peng F; Han YY; Lin HJ; Xu YZ; Zhou T; Xie G; Deng Y; Mao YQ; Yu LT; Yang L; Zhao YL
    Cell Physiol Biochem; 2012; 29(1-2):281-90. PubMed ID: 22415097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
    Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
    Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
    Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
    Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
    Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bafilomycin C1 induces G0/G1 cell-cycle arrest and mitochondrial-mediated apoptosis in human hepatocellular cancer SMMC7721 cells.
    Gao X; Han L; Ding N; Mu Y; Guan P; Hu C; Huang X
    J Antibiot (Tokyo); 2018 Sep; 71(9):808-817. PubMed ID: 29752478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
    Chen L; Pan J
    Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
    Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
    Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
    Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
    Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
    Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
    Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
    Shi X; Li H; Shi A; Yao H; Ke K; Dong C; Zhu Y; Qin Y; Ding Y; He YH; Liu X; Li L; Lei L; Hai Q; Chen W; Leung KS; Wong MH; Kung HF; Lin MC
    Oncol Rep; 2018 Sep; 40(3):1592-1600. PubMed ID: 29956794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma.
    Baek SY; Hwang UW; Suk HY; Kim YW
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32375410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.